Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Sun Pharma Announce FDA Approval of Xelpros to Treat Open-angle Glaucoma or Ocular Hypertension
Sun Pharma Announce FDA Approval of Xelpros to Treat Open-angle Glaucoma or Ocular Hypertension
Sun Pharma Announce FDA Approval of Xelpros to Treat Open-angle Glaucoma or Ocular Hypertension
Submitted by
admin
on September 14, 2018 - 10:59am
Source:
CP Wire
News Tags:
Sun Pharma
Xelpros
latanoprost
open angle glaucoma
Headline:
Sun Pharma Announce FDA Approval of Xelpros to Treat Open-angle Glaucoma or Ocular Hypertension
snippet:
Xelpros is the first and only form of latanoprost that is not formulated with benzalkonium chloride (BAK)
BAK is associated with increased incidence of Ocular Surface Disease (OSD)
Do Not Allow Advertisers to Use My Personal information